How Sanofi uses AI

Sanofi describes using AI in its clinical development organization to analyze historical trial data and disease patterns so study teams can estimate realistic timelines and predict the number of eligible participants at different locations before choosing where to run a trial. Christian Mornet, Sanofi's Clinical Digital Lead for Vaccines, says the approach spots patterns across prior studies "from any origin" to improve how trials are designed and targeted, aiming for more efficient and reliable recruitment than making educated guesses.

Sanofi's manufacturing and supply organization gives site teams AI and machine learning tools that search for similar deviations at other sites and in the past, and that automate the review and trending of minor deviations, the largest category of deviations. The executive vice president for manufacturing and supply reports that this cut deviation closure time. The same article describes SimplY, an AI powered yield analytics platform that flags production outliers, but states no number for it.

Sanofi and Deloitte spent more than two years building an AI, software as a service adverse event case intake platform, ConvergeHEALTH Safety, that automates the capture, entry and coding of safety information before it is reported to regulators worldwide. Stephen Kuske, Sanofi's global head of pharmacovigilance operations, said the collaboration let Sanofi optimize quality and efficiency at the same time for the first time, and Sanofi's head of digital pharmacovigilance, Anand Ramanathan, said the initiative frees pharmacovigilance staff to focus on patient safety. Deloitte reports that the initial deployment already improved case quality and case processing efficiency.